Oral News and Research

RSS

EU and U.S. regulatory authorities accept Biogen Idec’s BG-12 NDA for review

Today Biogen Idec announced that U.S. and EU regulatory authorities have accepted the company's marketing applications for the review of BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of multiple sclerosis.

10 May 2012

FDA AAC recommends approval of Pfizer’s tofacitinib for RA

Pfizer Inc. announced today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

10 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Dental fraud of £73 million revealed as experts call for system overhaul

...

9 May 2012

Botanical formula inhibits breast to lung cancer metastasis in mice

Scientists at Indiana University Health's Cancer Research Laboratory have found that a sophisticated botanical formula slows human breast cancer growth and inhibits breast to lung metastasis in mice. The formula contains extracts from medicinal mushrooms, medicinal herbs and purified nutritional compounds, and showed no toxic side-effects.

9 May 2012

Health budget focuses on dental and aged care

The states need to increase the number of public dental patients they treat or lose the reward payments offered by the federal government under its new $500 million dental package. A total of over $800 million of new money has come into the focal points of the health budget - dental and aged care.

9 May 2012

Non-drug therapy with NeuroStar TMS improves depression symptoms and QOL

New data released today at the annual meeting of the American Psychiatric Association show that patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy achieved significant improvements in both depression symptoms and in quality of life measurements.

9 May 2012

Current anticoagulant therapy to prevent stroke might not be sufficient for older women with AF

In a study that examined use of the anticoagulant medication warfarin and risk of stroke following a diagnosis of atrial fibrillation in older patients, women, especially those 75 years or older, had a higher risk of stroke than men, regardless of their risk profile and use of warfarin, suggesting that current anticoagulant therapy to prevent stroke might not be sufficient for older women, according to a study in the May 9 issue of JAMA.

9 May 2012

Rutin may inhibit formation of blood clots

A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis.

9 May 2012

Pfizer seeks FDA support for its new anti-rheumatoid arthritis pill

Pfizer is waiting for the Food and Drug Administration to approve its new pill for rheumatoid arthritis (RA) - the first oral biologic for treating this ailment.

8 May 2012

Oral zinc treatments may shorten duration of common cold symptoms in adults

Oral zinc treatments may shorten the duration of symptoms of the common cold in adults, although adverse effects are common, according to a study published in CMAJ.

8 May 2012

Viewpoints: Diabetes, future health ills & the GOP; Debate on FDA OTC plan; Sen. Brown's daughter's health insurance

A study of diabetes in overweight and obese youngsters bears an ominous warning about future health care trends in this country. It found that Type 2 diabetes, a new scourge among young people, progresses faster and is harder to treat in youngsters than in adults. ... Congressional Republicans, meanwhile, are bent on dismantling health care reforms that could greatly assist in curbing the obesity epidemic.

8 May 2012

Over $300 million set aside in the budget for dental assistance

The move was announced by federal Health Minister Tanya Plibersek at the weekend. It is claimed to provide $345.9m over three years to reduce the long waiting lists for public dental treatment. This could benefit 400,000 people. Ms Plibersek also announced that the Voluntary Dental Graduate Year Program will be increased from 50 to 100 placements per year by 2016 at a cost of $35.7 million over three years. “This funding boost will provide practice experience and professional development opportunities, including in under-serviced areas, to additional dental graduates,” she said.

8 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.

8 May 2012

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.

7 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

Unigene first quarter net loss decreases to $6.0 million

Unigene Laboratories, Inc., today announced financial results for the first quarter ended March 31, 2012.

7 May 2012

Oral nutriceutical restores vision to otherwise hopeless patients facing permanent loss

There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede. While injectable drugs called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle and have become the standard of care for patients with the fast-progressive form of macular degeneration, they are not foolproof.

7 May 2012

Energy/Sports drinks damage teeth enamel raising risk of cavities: Study

Researcher Poonam Jain, associate professor and director of community dentistry at the Southern Illinois University School of Dental Medicine said, “The big misconception is that energy drinks and sports drinks are healthier than soda for oral health. This study completely disproves that, because they erode or thin out the enamel of the teeth, leaving them more susceptible to decay and sensitivity.”

4 May 2012